Use of gastric acid suppressants may negatively impact survival outcomes in sarcoma patients treated with pazopanib
In patients with soft tissue sarcoma, the concomitant use of gastric acid suppressant (GAS) therapy and the anticancer therapeutic pazopanib (Votrient) was associated with significantly reduced progression-free survival and ...
Feb 14, 2019
0
0